Emergent BioSolutions Inc. 2009 10-K Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Emergent BioSolutions Inc. for the fiscal year ended December 31, 2009. Emergent is a biopharmaceutical company operating in two segments: Biodefense (focused on vaccines and therapies for bioterrorism agents, primarily anthrax) and Commercial (focused on vaccines for infectious diseases like tuberculosis and typhoid). The company's primary revenue driver is BioThrax, the only FDA-approved anthrax vaccine, sold almost exclusively to the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DoD).
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Total Revenues | $234.8 million | $178.6 million |
| Product Sales (BioThrax) | $217.2 million | $169.1 million |
| Contracts and Grants | $17.6 million | $9.4 million |
| Net Income (Attributable to Emergent) | $31.1 million | $20.7 million |
| Diluted EPS | $0.99 | $0.68 |
| Cash and Cash Equivalents | $102.9 million | $91.5 million |
| Total Debt (Principal) | $65.7 million | $57.2 million |
| Working Capital | $139.1 million | $98.9 million |
Note: Gross margin for product sales was approximately 78.7% in 2009 ($217.2M revenue vs. $46.3M cost of sales).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 31% year-over-year. Product sales rose 28% to $217.2 million, driven by an 8% increase in doses sold and a one-time price adjustment of approximately $34 million from HHS following FDA approval to extend BioThrax expiry dating from three to four years.
- Profitability: Net income attributable to Emergent increased 51% to $31.1 million, supported by higher revenues and a lower effective tax rate (32% in 2009 vs. 37% in 2008).
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 34% to $73.8 million. This included a $7.3 million impairment charge related to two facilities in Frederick, Maryland, classified as "held for sale," and increased litigation costs.
- Debt and Liquidity: The company increased its debt load to finance facility acquisitions (Baltimore and Gaithersburg) and manufacturing expansion. Cash balances grew by $11.5 million, despite significant investing outflows of $33.3 million for capital expenditures.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to continue deriving substantially all revenue from BioThrax sales to the U.S. government. Strategic priorities include expanding the anthrax franchise (pursuing post-exposure prophylaxis approval and reduced dosing schedules), growing the commercial pipeline (Tuberculosis, Typhoid), and expanding manufacturing capabilities in Lansing, Michigan, and Baltimore, Maryland.
Key Risks and Contingencies:
- Government Dependence: The company is highly dependent on U.S. government contracts. Future funding is subject to Congressional appropriations and competitive bidding. Contracts can be terminated for convenience.
- Manufacturing Risks: BioThrax manufacturing is complex and subject to FDA lot release requirements. The company relies on a single contract filler (Hollister-Stier) for vial filling, with a contract expiring in 2010.
- Legal Proceedings: The company is pursuing litigation against Protein Sciences Corporation (PSC) regarding a $10 million loan and asset purchase agreement, seeking damages of at least $13 million. PSC has not repaid the loan.
- Product Development: Commercial product candidates (e.g., Tuberculosis vaccine) are in various stages of clinical trials and have not yet generated product revenue. Success depends on regulatory approvals and external funding.
Investor Verification Checklist
- Contract Renewals: Verify the status of upcoming HHS and DoD procurement contracts for BioThrax and the potential impact of the 2010 expiration of the contract with Hollister-Stier Laboratories.
- Manufacturing Validation: Confirm the timeline and regulatory status for the new 50,000 sq. ft. manufacturing facility in Lansing, Michigan, and the renovation of the Baltimore facility.
- Legal Exposure: Monitor the outcome of the litigation against Protein Sciences Corporation and the status of the $10 million note receivable.
- Debt Covenants: Review compliance with debt covenants, specifically the book leverage ratio and debt coverage ratio required by HSBC and Fifth Third Bank.
- Commercial Pipeline Funding: Assess the company's ability to secure external government or philanthropic funding for commercial product candidates (e.g., Typhella, Tuberculosis vaccine) to offset R&D costs.